Health Bulletin 04/ March/ 2024

Bringing good news to the postgraduate medical aspirants, new DNB and FNB courses are going to commence at Lady Hardinge Medical College (LHMC).

Confirming this, the Director of the institute Subhas Giri informed that the institute aims to start DNB course in emergency medicine and FNB course in reproductive and foetal medicine.

Johnson & Johnson has announced that following a priority review, the U.S. Food and Drug Administration (FDA) has approved RYBREVANT (amivantamab-vmjw) in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test.

This FDA action converts the May 2021 accelerated approval of RYBREVANT to a full approval based on the confirmatory Phase 3 PAPILLON study.

For more information click on the link below:

Government committee to review doctors’ private practice and health sector reforms in J&K

The Jammu and Kashmir administration has established a high-level advisory committee to address private practice by government doctors and propose healthcare reforms. Led by Dr. Ajit Nagpal, the committee includes experts like Dr. Atul Kotwal and Dr. Yashpal. Its key objective is to regulate private practice while optimizing service conditions for doctors. This practice has sparked debate, with concerns about its impact on healthcare quality.

Drawing from global best practices, the committee aims to provide tailored recommendations for Jammu and Kashmir. These efforts seek to enhance healthcare accessibility, affordability, and quality across the region.

Holding Fortis Hospital and its gastroenterologist guilty of gross negligence, dereliction of duty and deficiency of service while providing treatment for choledocholithiasis, the district consumer disputes redressal commission (DCDRC), Kangra recently directed them to pay Rs 5 lakh compensation to the patient.

“The complainant, who had gone to Fortis Hospital during Covid-19 period for the treatment of Choledocholithiasis, was not treated properly and was subjected to another ERCP procedure in the month of August, 2021. Thus, the opposite parties are liable to pay a hefty compensation to the complainant for act of dereliction,” opined the District Consumer Court.

For more information click on the link below: